Pfizer

ZIRABEV

Manufacturer:

Pfizer

Zirabev HCPCS:

Q5118

HCPCS Code Descriptor:

Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

Category:

Q Code

Zirabev NDCs:

00069-0342-01, 00069-0315-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zirabev:

ZIRABEV is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5118 is aligned to the drug ZIRABEV.

Zirabev (bevacizumab) is a VEGF (Vascular Endothelial Growth Factor) protein inhibitor used to treat various types of cancer. This includes colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and certain types of brain tumors, among other types of cancer. Zirabev is manufactured by Pfizer and is biosimilar to Avastin (J9035). This medication is aligned to the HCPCS code Q5118 and has been since October 2019.

ACCESS PRICING AND MORE BY REGISTERING

Q5118 Added Date:

October 1, 2019

Q5118 Effective Date:

October 1, 2019

Q5118 Termination Date:

HCPCS Active

Zirabev billing and coding information can be found through Pfizer at the link below:
Zirabev patient assistance information can be found through Pfizer Oncology Together at the URL: https://www.zirabev.com/patientresources
ZIRABEV prescribing information can be found at the link below:
Information regarding ZIRABEV’s side effects can be found at MedlinePlus